Health Matters

Tag: Obesity Drugs

  • Eli Lilly 2026 Guidance Signals Momentum In Obesity Care

    Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and diabetes medicines. For Q4, Lilly…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Roche CT-388 Obesity Drug Posts 22.5% Weight Loss

    Roche has reported mid-stage results that put its lead obesity candidate closer to the front of a fast-moving race dominated by Eli Lilly and Novo Nordisk. The Swiss group said its once-weekly injectable Roche CT-388 obesity drug achieved up to 22.5% placebo-adjusted weight loss at 48 weeks in a phase 2 trial among participants who adhered to the treatment regimen.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in